Skip to content
OpenCapital
Get started

Definitive Healthcare Corp. DH EV / sales

EV / sales at other companies

Microsoft logo
MicrosoftMSFT
8.9×-1.7×
Veeva Systems logo
Veeva SystemsVEEV
7.1×-5.2×
IQVIA logo
IQVIAIQV
2.6×-0.3×
Clarivate logo
ClarivateCLVT
2.4×-0.4×
Health Catalyst logo
Health CatalystHCAT
0.7×-0.5×
Teladoc Health logo
Teladoc HealthTDOC
0.1×-0.2×

Other financials

Income statement

See full
Revenue$55.9M-5.5%
Gross profit$46.6M-5.0%
Operating income-$201.3M-8.9%
Net income-$138.6M-29.3%
EPS (diluted)-$1.32-38.9%

Balance sheet

See full
Cash & equivalents$157.6M+48.6%
Total debt$169.8M-6.0%
Total assets$514.7M-36.3%

Cash flow

See full
Operating cash flow$11.6M-55.6%
CapEx$3.2M-58.4%
Free cash flow$8.4M-54.5%

Valuation

See full
Market cap$87.68M-79.8%
Enterprise value$99.87M-81.2%
P/S0.4×-1.4×

Profitability

See full
Gross margin84.4%+1.0pp
Operating margin-101.1%-42.1pp
Net margin-71.5%-28.2pp
FCF margin12.1%-8.4pp

Returns & leverage

See full
Current ratio1.8×0.0×

Where this comes from

Calculated from Definitive Healthcare Corp.’s reported figures.

enterprise value/total revenue=0.6×

Based on the most recent quarter.

The official record: Definitive Healthcare Corp.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Definitive Healthcare Corp.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Definitive Healthcare Corp.'s EV / sales?
Definitive Healthcare Corp. (DH) reported EV / sales of 0.6× in Q1 2026.
How has Definitive Healthcare Corp.'s EV / sales changed year-over-year?
Definitive Healthcare Corp.'s EV / sales decreased by 63.5% year-over-year, from 1.6× to 0.6×.
What is the long-term trend for Definitive Healthcare Corp.'s EV / sales?
Over 4 years (2021 to 2025), Definitive Healthcare Corp.'s EV / sales has grown at a -46.4% compound annual growth rate (CAGR), from 15.3× to 1.3×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.